Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Plasma cell 9Thoracic 2Other hematologic neoplasm 2CNS 2Breast 2Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 30Injections 26Pemetrexed 15Interviews as Topic 15tislelizumab 13Specimen Handling 13Carboplatin 13Cisplatin 12Nivolumab 11atezolizumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Bevacizumab 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Platinum 6Paclitaxel 6Leucovorin 6Ipilimumab 6Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tocilizumab × Other solid neoplasm × 90 days × Clear all
NCT03448042 2026-05-28

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Genentech, Inc.

Phase 1 Active not recruiting
123 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡